Tumour lysis syndrome (TLS) is a rare but serious complication of cancer treatment. It is generally seen in patients with high tumour load or chemosensitive tumour after chemotherapy, and is more common with haematological malignancies like leukaemia and lymphoma when compared to solid tumours. TLS, occurring after radiotherapy (RT) in patients with solid tumours, is very rare.
INTRODUCTION
Tumour lysis syndrome (TLS) is a rare but serious complication of cancer treatment, which occurs secondary to massive tumour cell lysis, resulting in the release of large amounts of intracellular potassium, phosphate, and uric acid into systemic circulation (1) . TLS occurring after RT in patients with solid tumours is very rare (2) . We aimed to present TLS seen after RT for a vertebral tumoral mass in a patient with metastatic adenocarcinoma of unknown origin.
CASE REPORT
A 78 year-old woman who had hypertension admitted with a complaint of fatigue. She had fatigue and severe back pain for one month. On physical examination, her general condition was good. She was afebrile; blood pressure was 120/80, pulse was 78 per minute.
Hepatomegaly was detected on abdominal examination. The remaining examination was unremarkable. Her laboratory findings were as follows: haemoglobin: 13.8 g/dL, leukocyte: 9200/μL, platelet count: 210x10³/μL, serum urea: 35 mg/dL, creatinine: 0,6 mg/dL, Na: 145 mmol/L, K: 4, 2 mmol/L, uric acid: 5, 1 mg/dL, calcium: 9, 1 mg/dL, phosphorous: 3, 9 mg/dL, LDH: 620 IU/L, albumin: 3. Spontaneous TLS was related to adenocarcinoma with unknown origin in two of the reported cases. The authors suggest that liver metastasis may be related to a higher risk of TLS.
The current article includes a heterogeneous group of patients who had variable types of tumours and clinical and laboratory findings (6) . The only risk factor was high serum LDH levels in our patient. Liver metastasis was mentioned as a risk factor for TLS based on observational data, but it remains speculative. In our case, the dosage of RT is relatively low when compared to previous studies.
TLS is a reversible complication, especially when diagnosed early. Treatment consists of aggressive hydration, forced diuresis, allopurinol and rasbirucase. In patients unresponsive to medical therapy, renal replacement therapy (RRT) is the next step in the treatment. The indications of RRT in TLS are similar to those in patients with other types of acute kidney injury, although somewhat lower thresholds are used for TLS, because there is a high Bayrakci et al 5 potential risk for rapid potassium accumulation (1, 7) . If RRT is initiated early, renal survival is excellent (8) . When the type of tumour and type of treatment were taken into account, our patient with relatively low risk for TLS developed the syndrome, complicated with AKI, requiring RRT, and she was successfully treated by hemodialysis.
In conclusion, the relatively low incidence of TLS in solid tumours may be related to a low number of risk factors as well as under-diagnosis of the syndrome. Close monitoring, even in patients with low risk for TLS and early administration of preventive modalities, including aggressive hydration first, should be kept in mind.
